A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK Plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma

PURPOSE: Based on preclinical evidence of synergistic activity between MEK and EGFR inhibitors in pancreatic ductal adenocarcinoma (PDAC), we evaluated the safety and efficacy of selumetinib, a MEK1/2 inhibitor, plus erlotinib in patients with previously treated advanced PDAC. EXPERIMENTAL DESIGN: I...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Ko, Andrew H., Bekaii-Saab, Tanios, Van Ziffle, Jessica, Mirzoeva, Olga M., Joseph, Nancy, Talasaz, AmirAli, Kuhn, Peter, Tempero, Margaret A., Collisson, Eric A., Kelley, R. Kate, Venook, Alan P., Dito, Elizabeth, Ong, Anna, Ziyeh, Sharvina, Courtin, Ryan, Linetskaya, Regina, Tahiri, Sanaa, Korn, W. Michael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4703532/
https://ncbi.nlm.nih.gov/pubmed/26251290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0979
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak